The estimated Net Worth of Terri A Morrical is at least $4.81 million dollars as of 3 May 2021. Terri Morrical owns over 4,184 units of Neogen stock worth over $636,825 and over the last 21 years Terri sold NEOG stock worth over $4,177,305.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Terri Morrical NEOG stock SEC Form 4 insiders trading
Terri has made over 63 trades of the Neogen stock since 2003, according to the Form 4 filled with the SEC. Most recently Terri exercised 4,184 units of NEOG stock worth $262,337 on 3 May 2021.
The largest trade Terri's ever made was exercising 39,467 units of Neogen stock on 16 January 2020 worth over $1,517,901. On average, Terri trades about 6,994 units every 76 days since 2003. As of 3 May 2021 Terri still owns at least 41,759 units of Neogen stock.
You can see the complete history of Terri Morrical stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Terri Morrical's mailing address?
Terri's mailing address filed with the SEC is , , , , .
Insiders trading at Neogen
Over the last 24 years, insiders at Neogen have traded over $135,917,555 worth of Neogen stock and bought 195,554 units worth $4,379,833 . The most active insiders traders include James L Herbert, Jeffrey D Capello et Lon M Bohannon. On average, Neogen executives and independent directors trade stock every 11 days with the average trade being worth of $140,346. The most recent stock trade was executed by Ronald D Green on 29 August 2024, trading 4,446 units of NEOG stock currently worth $68,780.
What does Neogen do?
neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.
What does Neogen's logo look like?
Complete history of Terri Morrical stock trades at Neogen
Neogen executives and stock owners
Neogen executives and other stock owners filed with the SEC include:
-
John Adent,
President, Chief Executive Officer, Director -
Steven Quinlan,
Chief Financial Officer, Vice President, Secretary -
John Edward Adent,
Pres, CEO & Director -
Jason Lilly,
Vice President - International Business -
Jerome Hagedorn,
Vice President - Food Safety operations -
Douglas E. Jones,
VP & Chief Commercial Officer -
Steven J. Quinlan,
VP & CFO -
James Borel,
Lead Independent Chairman of the Board -
James Tobin,
Independent Director -
Ronald Green,
Independent Director -
William Boehm,
Independent Director -
Darci Vetter,
Independent Director -
G. Bruce Papesh,
Independent Director -
Doug Jones,
Chief Commercial Officer -
Amy M. Rocklin Ph.D.,
VP, Gen. Counsel & Corp. Sec. -
Julie A. Mann,
VP & Chief HR Officer -
Rod Poland,
Director of Corp. Communications -
Amy Rocklin Ph.D.,
VP & Gen. Counsel -
Sarah Demey,
Admin. Mang. -
Bruce Papesh,
Director -
A Charles Fischer,
Director -
Richard E Jr Calk,
President & COO -
Richard T Crowder,
Director -
Jack C Parnell,
Director -
Clayton K Yeutter,
Director -
Thomas H Reed,
Director -
Terri A Morrical,
-
David H. Naemura,
Chief Financial Officer -
Edward Bradley,
V.P. Sales and Marketing -
Aashima Gupta,
Director -
Jeffrey D Capello,
Director -
Rex L Hamilton,
Vice President -
Herbert D Doan,
Director -
Gordon E Guyer,
Director -
James L Herbert,
Director -
Joseph M Madden,
V.P. Scientific Affairs -
Richard R Current,
Vice President & CFO -
Anthony E Maltese,
VP Business Development -
Kenneth V Kodilla,
Vice President -
Lon M Bohannon,
COO -
Mark A Mozola,
Vice President of R&D -
Leonard E Heller,
Director -
Robert M Book,
Director -
Stephen K. Snyder,
Former Pres. and COO -
Paul S Satoh,
V.P Research and Development -
Rafael A Rodriguez,
Director -
Catherine E Woteki,
Director -
Amy M Rocklin,
Chief Legal Officer -
John Patrick Moylan,
Chief Accounting Officer